Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant two component COVID-19 vaccine - Jiangsu Rec-Biotechnology

Next Previous
X
Search
Drug Profile

Recombinant two component COVID-19 vaccine - Jiangsu Rec-Biotechnology

Alternative Names: Recombinant two-component COVID-19 vaccine (CHO cell) - Jiangsu Rec-Biotechnology; ReCOV; ReCOV - Jiangsu Rec-Biotechnology

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Provincial Center for Disease Control and Prevention; Jiangsu Rec-Biotechnology
  • Developer Jiangsu Rec-Biotechnology
  • Class COVID-19 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in New Zealand (IM, Injection)
  • 29 Dec 2023 Jiangsu Rec-Biotechnology completes a phase III trial in COVID-2019 infections (In adults, In the elderly, Prevention) in Nepal, Russia (IM) (NCT05398848)
  • 22 Mar 2023 Registered for COVID-2019 infections (Prevention) in Mongolia (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top